Preparation method and application of high-activity human SSX1 protein

Through self-induction medium and high pH dissolution buffer purification technology, the problems of expensive inducers in the preparation of human SSX1 protein in the prior art are solved, and high inclusion rate are achieved, efficient and low-loss production is achieved, and high activity and High-purity SSX1 protein, suitable for industrial-scale production.

CN119082158APending Publication Date: 2024-12-06GENE TECH SHANGHAI COMPANY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411207561.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art has problems such as expensive inducer, high inclusion rate, complicated regeneration steps, and poor plasmid stability when preparing highly active human SSX1 protein, resulting in high production costs and low yields, especially not suitable for industrial-scale production.

Method used

采用自诱导培养基培养大肠杆菌,利用高pH溶解缓冲液纯化重组SSX1蛋白,通过Sarkosyl、CHAPS和甘氨酸等促溶剂处理包涵体,实现蛋白的高效溶解和纯化,避免了IPTG的使用,简化了操作流程。

Benefits of technology

It improves the yield and purity of recombinant human SSX1 protein, simplifies the operating process, reduces production costs, and obtains high immunoactive proteins, which are suitable for industrial-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005019621200000111
    Figure BDA0005019621200000111
  • Figure BDA0005019621200000112
    Figure BDA0005019621200000112
  • Figure BDA0005019621200000171
    Figure BDA0005019621200000171
Patent Text Reader

Abstract

The invention provides a preparation method and application of a high-activity human SSX1 protein. The invention provides a preparation method of a recombinant human SSX1 protein. When the method is used for preparing the SSX1 protein, the operation process is simplified, the consumed time is shortened, the yield of the recombinant human SSX1 protein is improved, the recombinant human SSX1 protein can be efficiently expressed and produced, and the obtained recombinant human SSX1 protein is high in purity and immunocompetence.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of gene engineering and bioengineering, and specifically relates to a preparation method of a highly active human SSX1 protein and its application. Background Art

[0002] Malignant tumors have seriously affected life and health. A large number of studies have shown that most tumor tissues have tumor antigens that are different from normal tissues. Tumor antigens are expected to be used as immunogens for tumor vaccines, targets for immunotherapy, and biomarkers for early screening or diagnosis and prognosis. Among these antigens, cancer-testis antigens (CT antigens) have been shown to have broad immunogenicity and are a type of antigen that is expressed in a variety of tumor tissues but not in normal tissues except testicles.

[0003] Synovial Sarcoma X breakpoint (SSX) is a common cancer-testis antigen. The SSX family includes ten highly homologous proteins, and SSX1 is expressed most frequently in human sarcomas. The SSX1 gene is located on human chromosome Xp11.23-p11.22, encoding 188 amino acids, and the molecular weight of the protein is about 22kDa. SSX1 is expressed in a variety of human cancer cells, including but not limited to fibrosarcoma, liver cancer, lung cancer, breast cancer, colon cancer, prostate cancer and chronic myeloma cell leukemia, but is only expressed in the testis in normal tissues. As a target for the above-mentioned cancers, SSX1 protein can not only be used as a marker for the diagnosis of the above-mentioned diseases, but also can be used to produce preventive agents and / or therapeutic agents, such as antibodies or T cell receptors, for the above-mentioned diseases. Diagnostic agents (such as autoantibody detection agents), preventive agents or therapeutic agents (such as vaccines) all rely on high-purity and highly immunoactive SSX1 proteins.

[0004] The E. coli genetic engineering bacteria currently used in production in this field are almost all inducible expression systems. The expression of foreign proteins is induced by temperature induction, chemical inducers, etc., which has some disadvantages, such as: the addition of expensive inducers increases the production cost, and a large amount of foreign proteins are produced in a short time after induction, which is easy to form inclusion bodies. Generally, more than 50% of the foreign proteins formed are inclusion body proteins without biological activity, and some even exceed 80%. After the inclusion body proteins are formed, subsequent cumbersome renaturation steps are required for some proteins to restore biological activity, but the renaturation step is very labor-intensive, which further increases the production cost of foreign proteins.

[0005] Although constitutive E. coli genetically engineered bacteria can overcome some of the above shortcomings to a certain extent, reduce costs and prevent foreign proteins from forming inclusion bodies, the heavy metabolic burden of cells containing plasmids in constitutive E. coli genetically engineered bacteria makes the specific growth rate of the two cells very different compared with cells without plasmids, which can easily lead to cells losing plasmids becoming the dominant group during the culture process, reducing plasmid stability and yield. Since it is difficult to optimize the fermentation process of constitutive E. coli genetically engineered bacteria, people in the field generally believe that constitutive expression systems are not suitable for industrial-scale production.

[0006] Previously, SSX1 protein was usually prepared by culturing E. coli in LB medium, inducing expression with IPTG, dissolving inclusion bodies with 8M urea, affinity purification, protein renaturation, and enzymatic removal of fusion tags. However, this type of culture requires multiple measurements of bacterial abundance to ensure that the inducer is added at the appropriate time. The inducer is toxic, which slows down the growth rate of the bacteria and reduces the upper limit of bacterial abundance in the culture product. The purification of SSX1 protein in inclusion bodies often completely loses its natural form after being treated with high-concentration denaturants, and requires subsequent cumbersome renaturation steps to restore some of the protein's biological activity. However, the renaturation step is very labor-intensive and the renaturation yield is low, which often becomes a bottleneck for improving protein yield. Enzymatic removal of fusion tags after protein renaturation further increases the production cost of exogenous proteins.

[0007] Since IPTG is not metabolized, it specifically induces the expression of exogenous proteins in cells. It is not affected by cell metabolism, and the induction effect is sustained and stable. Since IPTG is potentially toxic to the human body, when IPTG is used to induce the expression of recombinant drugs for human use, it will have an adverse effect on the final product. On the other hand, the price of IPTG is also relatively expensive, especially when induction is carried out in a larger volume fermenter, the use of IPTG will increase the fermentation cost. In particular, when preparing "recombinant human" proteins and for immune proteins related to human use (antigen vaccines), the toxicity of IPTG should be avoided as much as possible to meet clinical needs.

[0008] Therefore, there is a need in the art to further optimize the recombinant expression and purification strategies of SSX1 protein in order to achieve efficient and low-loss production. Summary of the invention

[0009] The purpose of the present invention is to provide a preparation method of highly active human SSX1 protein and its application.

[0010] In the first aspect of the present invention, a method for recombinantly expressing human SSX1 protein is provided, comprising: (1) providing recombinant Escherichia coli cells, wherein the Escherichia coli cells contain a recombinant expression cassette, wherein the recombinant expression cassette contains a human SSX1 protein coding sequence; (2) culturing the recombinant Escherichia coli cells of (1) to express the human SSX1 protein; performing cell lysis after expression to obtain a lysis product; and isolating inclusion bodies; (3) treating the inclusion bodies of (2) with a human SSX1 protein chaotropic agent at high pH; dissolving the protein with a high pH dissolution buffer containing a human SSX1 protein chaotropic agent; and purifying with a purification buffer containing a human SSX1 protein chaotropic agent to obtain an active human SSX1 protein purified product; wherein the human SSX1 protein chaotropic agent comprises: 0.1-1% Sarkosyl, 10-100mM CHAPS, 10-120mM glycine, and the high pH is pH10.0-13.0.

[0011] In the present invention, unless otherwise specified, the "amount" or "concentration" mentioned refers to the "final concentration".

[0012] In one or more embodiments, the amount of Sarkosyl (sodium lauryl sarcosine) is 0.2-0.8% (m / v), such as 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.9%.

[0013] In one or more embodiments, the amount of CHAPS (3-[(3-cholamidopropyl)dimethylamino]propanesulfonic acid inner salt) is 15-80 mM, such as 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 90 mM.

[0014] In one or more embodiments, the amount of glycine is 20-100 mM, such as 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 110 mM.

[0015] In one or more embodiments, the high pH is pH 10.0-13.0, preferably pH 10.5, pH 11, pH 11.5, pH 12, pH 12.5 or pH 12.8.

[0016] In one or more embodiments, the human SSX1 protein coding sequence is prepared by artificial synthesis.

[0017] In one or more embodiments, the recombinant expression cassette is located in an expression vector.

[0018] In one or more embodiments, the expression vector is a pET expression vector.

[0019] In one or more embodiments, the E. coli cell is E. coli BL21 (DE3).

[0020] In one or more embodiments, in step (1), the culture is carried out using an autoinduction medium, wherein the autoinduction medium does not contain a chemical inducer such as IPTG; preferably, the autoinduction medium comprises: peptone, yeast extract, glycerol, lactose, glucose, Na 2 HPO 4 , NH 4 Cl, KH 2 PO 4 , Na 2 SO 4 , MgSO 4 .

[0021] In one or more embodiments, in step (1), the culture is first carried out at a temperature of 37±3°C, preferably 37±2°C, and more preferably 37±1°C; then, the culture is changed to a temperature of 20±3°C, preferably 20±2°C, and more preferably 20±1°C.

[0022] In one or more embodiments, in step (1), the culture is first carried out at a temperature of 37±3°C, preferably 37±2°C, and more preferably 37±1°C; after culturing for 2±1 hours, preferably 2±0.5 hours, the culture is switched to a temperature of 20±3°C, preferably 20±2°C, and more preferably 20±1°C.

[0023] In one or more embodiments, in step (2), after expression, the cells are enriched (eg, collected by centrifugation) and then cell lysed.

[0024] In one or more embodiments, the autoinduction medium comprises: peptone 10 g / L, yeast extract 5 g / L, glycerol 5 g / L, lactose 2 g / L, glucose 0.5 g / L, Na 2 HPO 4 25mmol / L, NH 4 Cl 50mmol / L, KH 2 PO 4 25mmol / L, Na 2 SO 4 5mmol / L, MgSO 4 2mmol / L, wherein the dosage of each component may fluctuate within 60%, within 50%, within 40%, within 30%, within 20%, within 10% or within 5%.

[0025] In one or more embodiments, in step (2), the bacteria are treated with a lysis buffer sufficient to cause cell lysis to cause cell lysis; preferably, the lysis buffer contains an effective amount of: lysozyme, phosphate, sodium chloride, imidazole, glycerol, TCEP, PMSF; preferably, the lysis buffer is pH 7.5±0.5 (preferably pH 7.5±0.3, more preferably pH 7.5±0.2 or pH 7.5±0.1).

[0026] In one or more embodiments, after the lysis buffer treatment, the cells are physically disrupted; more preferably, the cells are ultrasonically disrupted in an ice bath;

[0027] In one or more embodiments, nuclease and MgCl are added to the lysate. 2 , incubate at 25±3°C (preferably, 25±2°C or 25±1°C); and separate and obtain inclusion bodies.

[0028] In one or more embodiments, the lysis buffer comprises: 0.2 mg / mL lysozyme, 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, 5% (v / v) glycerol, 1 mM TCEP, 1 mM PMSF, wherein the amount of each component may fluctuate within 60%, within 50%, within 40%, within 30%, within 20%, within 10% or within 5%.

[0029] In one or more embodiments, 30 U / mL nuclease, 3 mM MgCl 2 The amount of each component may fluctuate within 60%, within 50%, within 40%, within 30%, within 20%, within 10% or within 5%.

[0030] In one or more embodiments, in step (3), the high pH dissolution buffer comprises: a human SSX1 protein chaotropic agent, and: phosphate, sodium chloride, imidazole, glycerol, PMSF, and TCEP.

[0031] In one or more embodiments, the high pH dissolution buffer includes: 20mM phosphate, 500mM sodium chloride, 10mM imidazole, 5% (v / v) glycerol, 1mM PMSF, and 2mM TCEP; wherein each component can float up and down by 60%, preferably float up and down by 50%, and more preferably float up and down by 40%, such as floating by 30%, 20%, 15%, 10%, 5% or 2%.

[0032] In one or more embodiments, in step (3), the purification buffer containing the human SSX1 protein dissolving agent includes: human SSX1 protein dissolving agent, and phosphate, sodium chloride, imidazole, and glycerol; preferably, the purification buffer has a pH of 7.5±0.5.

[0033] In one or more embodiments, the purification buffer includes purification buffer 1, purification buffer 2, and purification buffer 3.

[0034] In one or more embodiments, the purification buffer 1 comprises: 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, SSX1 protein chaotropic agent (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), and 5% glycerol; wherein each component can fluctuate up and down by 60%, preferably up and down by 50%, and more preferably up and down by 40%, such as fluctuating by 30%, 20%, 15%, 10%, 5% or 2%.

[0035] In one or more embodiments, the purification buffer 2 comprises: 20 mM phosphate, 500 mM sodium chloride, 70 mM imidazole, SSX1 protein chaotropic agent (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), and 5% glycerol; wherein each component can fluctuate up and down by 60%, preferably up and down by 50%, and more preferably up and down by 40%, such as fluctuating by 30%, 20%, 15%, 10%, 5% or 2%.

[0036] In one or more embodiments, the purification buffer 3 includes: 20mM phosphate, 500mM sodium chloride, 250mM imidazole, SSX1 protein chaotropic agent (0.3% Sarkosyl, 20mM CHAPS, 50mM glycine), and 5% glycerol; wherein each component can fluctuate up and down by 60%, preferably up and down by 50%, and more preferably up and down by 40%, such as fluctuating by 30%, 20%, 15%, 10%, 5% or 2%.

[0037] In one or more embodiments, the amino acid sequence of the human SSX1 protein is as shown in SEQ ID NO:2; preferably, the coding sequence of the human SSX1 protein is as shown in SEQ ID NO:1.

[0038] In another aspect of the present invention, there is provided a use of any of the above methods for recombinantly expressing human SSX1 protein, wherein the human SSX1 protein has high immunological activity.

[0039] In another aspect of the present invention, there is provided a kit for recombinantly expressing human SSX1 protein, comprising:

[0040] (a) a high pH dissolution buffer containing a human SSX1 protein dissolving agent; the human SSX1 protein dissolving agent comprises: 0.1-1% Sarkosyl, 10-100 mM CHAPS, 10-120 mM glycine, and the high pH is pH 10.0-13.0;

[0041] (b) A recombinant E. coli cell, wherein the E. coli cell comprises a recombinant expression cassette, wherein the recombinant expression cassette comprises a human SSX1 protein coding sequence.

[0042] In one or more embodiments, the kit optionally further comprises:

[0043] (c) Autoinduction medium includes: peptone, yeast extract, glycerol, lactose, glucose, Na 2 HPO 4 , NH 4 Cl, KH 2 PO 4 , Na 2 SO 4 , MgSO 4 , does not contain chemical inducers such as IPTG;

[0044] (d) a purification buffer containing a human SSX1 protein dissolving agent, comprising: a human SSX1 protein dissolving agent, and phosphate, sodium chloride, imidazole, and glycerol; preferably, the purification buffer has a pH of 7.5±0.5;

[0045] (e) lysis buffer; preferably, the lysis buffer comprises effective amounts of: lysozyme, phosphate, sodium chloride, imidazole, glycerol, TCEP, PMSF;

[0046] (f) Nuclease and MgCl 2 ;

[0047] (g) Purification buffer; preferably, it comprises: SSX1 protein chaotropic agent, phosphate, sodium chloride, glycerol, imidazole; preferably, the purification buffer has a pH of 7.5±0.5.

[0048] In another aspect of the present invention, there is provided use of the kit in recombinantly expressing human SSX1 protein.

[0049] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 , The inclusion bodies were dissolved in a high pH dissolution buffer containing an SSX1 protein promoter, and the purified SSX1 protein was detected by SDS-PAGE.

[0051] Figure 2 , The inclusion bodies were dissolved in a dissolution buffer containing 8 M urea, and the purified SSX1 protein was detected by SDS-PAGE.

[0052] Figure 3 , SDS-PAGE detection diagram of dialyzed renatured SSX1 protein.

[0053] Figure 4 , SSX1 protein immunoactivity determination, and fitting a four-parameter curve with the logarithm of the Anti-SSX1 polyclonal antibody dilution ratio as the horizontal axis and the signal value as the vertical axis.

[0054] Figure 5 , SSX1 antibody positive human serum sample detection diagram. DETAILED DESCRIPTION

[0055] In order to overcome the problem that it is difficult to efficiently obtain highly active recombinant human SSX1 protein in the art, the inventors have conducted in-depth research and provided a method for preparing recombinant human SSX1 protein. The method for preparing SSX1 protein simplifies the operation process, improves the yield of recombinant human SSX1 protein, can efficiently express and produce recombinant human SSX1 protein, and the obtained recombinant human SSX1 protein has high purity and high immunological activity.

[0056] As used herein, the "expression cassette" refers to a gene expression system that contains all necessary elements required to express a target polypeptide / protein (human SSX1 protein in the present invention), which generally includes the following exogenous elements: a promoter, a gene sequence encoding a polypeptide, a terminator; in addition, it may optionally include a signal peptide coding sequence, etc. These elements are operably linked.

[0057] As used herein, "exogenous" or "heterologous" refers to the relationship between two or more nucleic acid or protein sequences that are derived from different sources. For example, a promoter is exogenous to a gene of interest if the combination of the promoter and the gene of interest sequence does not normally occur in nature. A particular sequence is "exogenous" to the cell into which it is inserted.

[0058] As used herein, the kit refers to a package / box that is convenient for commercial-scale production and use, which usually contains a container / small package, and the culture medium, solution, single component or component of the present invention can be placed in the container / small package.

[0059] As used herein, the term "operably linked" or "operably connected" refers to the functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example, a promoter region is placed at a specific position relative to the target gene nucleic acid sequence, so that the transcription of the nucleic acid sequence is guided by the promoter region, and thus the promoter region is "operably linked" to the nucleic acid sequence.

[0060] As used herein, the terms “containing”, “having” or “including” include “comprising”, “mainly consisting of…”, “substantially consisting of…”, and “consisting of…”; “mainly consisting of…”, “substantially consisting of…” and “consisting of…” are subordinate concepts of “containing”, “having” or “including”.

[0061] As used herein, the "high pH (value)" refers to a pH value greater than 10 (at room temperature).

[0062] In the present invention, the human SSX1 protein can be full-length, active fragments, or analogs or derivatives thereof. As is known in the art, substitution, deletion or insertion of a few amino acids or amino acid sequences will not substantially change the function of the polypeptide encoded thereby. The present invention relates to homologous sequences to the above-mentioned functional polypeptides, preferably with a homology of more than 70%, more than 80%, more than 90%, more than 93%, more than 95% or more than 97%, more preferably, for example, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, and these polypeptide variants also have similar functions to the aforementioned polypeptides.

[0063] In a preferred embodiment, the method comprises the following steps: 1) synthesizing the whole human SSX1 gene; 2) cloning the whole SSX1 gene fragment into an expression vector; 3) constructing a recombinant bacterium, culturing the recombinant bacterium in an autoinduction medium to express the SSX1 protein; 4) treating the bacterial lysate with an SSX1 protein promoter and high pH; 5) purifying the SSX1 protein by affinity chromatography. The method for preparing a recombinant human SSX1 protein of the present invention uses Escherichia coli and an autoinduction medium to express a large amount of recombinant human SSX1 protein, and uses an SSX1 protein promoter to purify the SSX1 protein, thereby increasing the yield of the recombinant human SSX1 protein, being able to efficiently express and produce the recombinant human SSX1 protein, and obtaining a recombinant human SSX1 protein with high purity and high immunological activity.

[0064] In a preferred embodiment, the recombinant plasmid construction steps are as follows: 1) optimizing the codons for expressing the recombinant SSX1 protein in Escherichia coli and synthesizing the optimized gene fragment; 2) connecting the gene fragment to the expression vector, and the encoded recombinant SSX1 protein has His-tags at both ends; 3) transforming the ligated product into Escherichia coli DH5α competent cells, screening positive transformants, expanding the culture after Sanger sequencing verification, and extracting the recombinant plasmid.

[0065] In a preferred embodiment, the steps for preparing the recombinant bacteria are as follows: 1) transforming the recombinant plasmid into competent Escherichia coli cells; 2) picking at least 3 single colonies to culture in a small amount of LB medium, and then inoculating in a small amount of auto-induction medium for culture, and screening strains that efficiently express the recombinant SSX1 protein; 3) inoculating the strains that efficiently express the recombinant SSX1 protein into LB medium and culturing to the logarithmic growth phase, adding glycerol and freezing as seed bacteria.

[0066] In a preferred embodiment, the steps of expressing the recombinant SSX1 protein by the recombinant bacteria are as follows: 1) the recombinant bacterial seed bacteria are inoculated into LB liquid culture medium and cultured for 8 to 20 hours; 2) the culture is inoculated into the autoinduction medium at an inoculum size of 1‰ to 1%; 3) the culture is cultured in a constant temperature horizontal oscillator at 200 to 300 rpm, first at 37°C for 1 to 6 hours, and then at 17 to 30°C for 10 to 24 hours; 4) the bacteria are collected by filtration or centrifugation, and the liquid culture medium is removed.

[0067] In a preferred embodiment, the steps of treating the bacterial lysis product with a SSX1 protein dissolution agent and a high pH include: 1) resuspending the recombinant bacterial culture in a lysis buffer, lysing the bacteria, and separating the supernatant and the precipitate; 2) adding a high pH dissolution buffer containing an SSX1 protein dissolution agent after washing the lysis precipitate, and incubating for a period of time to promote protein dissolution; 3) separating the supernatant and the precipitate, and purifying the supernatant using an affinity chromatography column, and the purification buffer contains an SSX1 protein dissolution agent.

[0068] More preferably, the bacterial cells are ultrasonically disrupted and lysed at a power of 100 to 500 W, ultrasonically for 4 seconds, then stopped for 6 seconds, ultrasonically for 15 minutes and then stopped for 5 minutes, for a total of 15 to 60 minutes.

[0069] In a preferred embodiment, the SSX1 protein dissolving agent is preferably 0.1-1% Sarkosyl, 10-100mM CHAPS, 10-120mM glycine. The dissolution buffer contains 10-50mM phosphate, 50-500mM sodium chloride, 10-500mM imidazole, SSX1 protein dissolving agent (0.1%-1% Sarkosyl, 10-100mM CHAPS, 10-120mM glycine), 1-10% glycerol; preferably also includes PMSF, TCEP; pH 10.0-13.0.

[0070] In a preferred embodiment, the purification buffer contains 10-50 mM phosphate, 50-500 mM sodium chloride, 10-500 mM imidazole, SSX1 protein chaotropic agent (0.1%-1% Sarkosyl, 10-100 mM CHAPS, 10-120 mM glycine), 1-10% glycerol, pH 7.5-8.5.

[0071] The present invention also provides a kit for recombinantly expressing human SSX1 protein, comprising: (a) an SSX1 protein chaotropic agent, comprising: 0.1% to 1% Sarkosyl, 10 to 100 mM CHAPS, and 10 to 120 mM glycine; and (b) a recombinant Escherichia coli cell, wherein the Escherichia coli cell comprises a recombinant expression cassette, and the recombinant expression cassette contains a human SSX1 protein coding sequence.

[0072] In a preferred embodiment, the kit may further include: (c) an autoinduction medium comprising: peptone, yeast extract, glycerol, lactose, glucose, Na 2 HPO 4 , NH 4 Cl, KH 2 PO 4 , Na 2 SO 4 , MgSO 4 ; (d) lysis buffer; preferably, the lysis buffer comprises an effective amount of: lysozyme, phosphate, sodium chloride, imidazole, glycerol, TCEP, PMSF; (e) nuclease and MgCl 2 ; (f) purification buffer; preferably, it comprises: SSX1 protein chaotropic agent, phosphate, sodium chloride, glycerol, imidazole; preferably, the purification buffer is pH 7.5±0.5.

[0073] The present invention also provides a detection kit for SSX1-specific IgG antibodies, comprising a solid phase carrier coated with an antigen prepared according to the above-mentioned method for preparing the SSX1 protein.

[0074] The present invention also provides a detection method of a detection kit for SSX1-specific IgG antibodies, comprising the following steps:

[0075] 1) Mixing the solid phase carrier and the sample to be tested and reacting them, removing the supernatant after the reaction, washing and removing other non-specific binding components to obtain a solid phase carrier-antigen-IgG complex;

[0076] 2) adding enzyme-labeled anti-IgG secondary antibody to the solid phase carrier-antigen-IgG complex, mixing and reacting, removing the supernatant after the reaction, and obtaining a solid phase carrier-antigen-IgG-anti-IgG secondary antibody-enzyme complex;

[0077] 3) adding a luminescent or chromogenic substrate to the solid phase carrier-antigen-IgG-anti-IgG secondary antibody-enzyme complex and reacting, and detecting the signal intensity;

[0078] 4) Using a calibrator of known concentration, a signal intensity standard curve is drawn, and the signal intensity obtained in step 3) is compared with the standard curve to calculate the content of specific IgG in the serum sample to be tested.

[0079] Due to the implementation of the above technical solutions, the present invention has the following advantages compared with the prior art: the method of the present invention simplifies the operation process for preparing SSX1 protein, improves the yield of recombinant human SSX1 protein, can efficiently express and produce recombinant human SSX1 protein, and the obtained recombinant human SSX1 protein has high purity and high immunological activity. This enables the recombinant human SSX1 protein to be further applied to the detection of specific IgG antibodies with high sensitivity.

[0080] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, Science Press, or according to the conditions recommended by the manufacturer.

[0081] Example 1: Construction of human SSX1 protein expression recombinant plasmid pET28b-SSX1

[0082] Codon optimization was performed on the amino acid sequence of human SSX1 protein (Sequence ID: NP_001265620.1), and an optimized gene fragment was synthesized. Hind III / Xho I restriction site sequences were added at both ends. The SSX1 gene was about 564 bp in size, and its nucleotide sequence is shown in SEQ ID NO: 1. The optimized nucleotide sequence is only about 76% identical to the nucleotide sequence in the NCBI database, and the underlined nucleotides are the optimized nucleotides.

[0083] SSX1 nucleic acid sequence (SEQ ID NO: 1; 564 nt):

[0084]

[0085] The sequence of recombinantly expressed human SSX1 protein is shown in SEQ ID NO:2.

[0086] SSX1 amino acid sequence (SEQ ID NO:2; 188aa):

[0087]

[0088] The pET28b vector and the synthesized human SSX1 gene fragment were double-digested with Hind III / Xho I, recovered and purified by gel electrophoresis, and the two gene fragments were connected by DNA ligase.

[0089] The ligation product was transformed into E. coli DH5α competent cells and coated on LB plates. After inverted culture overnight, positive transformants were picked out, and the plasmid was extracted after sequencing to confirm the accuracy, thus obtaining the recombinant plasmid pET28b-SSX1.

[0090] Example 2: Construction of recombinant bacteria BL21(DE3) / pET28b-SSX1

[0091] The recombinant plasmid pET28b-SSX1 was transformed into competent E. coli BL21 (DE3), and 3 single colonies were picked to culture in a small amount of LB medium, and then inoculated into a small amount of autoinduction medium for culture to screen strains that efficiently expressed the recombinant SSX1 protein.

[0092] The strain expressing recombinant SSX1 protein efficiently was inoculated into LB medium and cultured to the logarithmic growth phase, and then frozen after adding glycerol as seed bacteria.

[0093] Example 3: Expression of SSX1 protein

[0094] Activation of glycerol bacteria: Take 10 μL of recombinant BL21 (DE3) / pET28b-SSX1 glycerol bacteria into 2 mL of liquid LB medium, add Kana antibiotics at a final concentration of 100 μg / mL, and culture at 37°C, 220 rpm, overnight.

[0095] Self-induced expression: inoculate 80 mL of self-induction medium at a rate of 1‰, culture at 37°C, 220 rpm, for 2 h, then transfer to 20°C, 220 rpm, and culture for 16 h.

[0096] The formula of the autoinduction medium is: peptone 10g / L, yeast extract 5g / L, glycerol 5g / L, lactose 2g / L, glucose 0.5g / L, Na 2 HPO 4 25mmol / L, NH 4 Cl 50mmol / L, KH 2 PO 4 25mmol / L, Na 2 SO 4 5mmol / L, MgSO 4 2mmol / L.

[0097] Example 4. Collection, lysis and inclusion body preparation of bacteria

[0098] Bacterial collection and lysis: Bacteria were collected by centrifugation at 10000g for 10 min, washed once with 10 mL PBS, and resuspended in 4 mL lysis buffer (containing 0.2 mg / mL lysozyme, 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, 5% (v / v) glycerol, 1 mM TCEP, 1 mM PMSF, pH 7.5).

[0099] Ultrasonic disruption was performed in an ice bath at a power of 150 W, with a cycle of 4 s for 4 seconds and a rest period of 6 seconds. Ultrasonication was performed for 15 minutes and then a rest period of 5 minutes, for a total of 30 minutes.

[0100] Add 30U / mL nuclease and 3mM MgCl to the lysate. 2 , 25℃ water bath for 10min.

[0101] The supernatant and precipitate were separated by low-temperature centrifugation at 10000g for 10 min, and the precipitate was washed with 1M urea solution (containing 1M urea, 20mM phosphate, 500mM NaCl, 10mM imidazole, 0.5mM TCEP, pH7.5) for 1h by low-temperature shaking. The supernatant and precipitate were separated by low-temperature centrifugation at 10000g for 10 min again, and the supernatant was discarded to obtain the inclusion bodies.

[0102] Example 5: Inclusion body solubilization and SSX1 protein purification

[0103] Add high pH dissolution buffer containing SSX1 protein chaotropic agent to the inclusion body and shake at low temperature (2-8°C) for 2 h. The high pH dissolution buffer containing SSX1 protein chaotropic agent contains 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, SSX1 protein chaotropic agent (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), 5% glycerol, 1 mM PMSF, 2 mM TCEP, pH 12.5. Centrifuge at 10000g for 10 min to separate the supernatant and precipitate, adjust the supernatant pH to 7.5, and filter the supernatant using a 0.22 μm syringe filter.

[0104] The nickel column was equilibrated with purification buffer 1 (containing 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, SSX1 protein promoter (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), 5% glycerol, pH 7.5), and the supernatant after filtration was loaded. After loading, non-specific binding proteins were washed away with 5 column volumes of purification buffer 2 (containing 20 mM phosphate, 500 mM sodium chloride, 70 mM imidazole, SSX1 protein promoter (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), 5% glycerol, pH 7.5). Finally, the SSX1 protein was eluted with 5 column volumes of purification buffer 3 (containing 20 mM phosphate, 500 mM sodium chloride, 250 mM imidazole, SSX1 protein chaotropic agent (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine), 5% glycerol, pH 7.5) to obtain purified SSX1 protein.

[0105] Depend on Figure 1 It can be seen that the high pH dissolution buffer containing the SSX1 protein chaotropic agent fully dissolves the SSX1 protein in the inclusion body, and the purified protein contains a low amount of SSX1 protein dimer. The purity and total amount of the purified protein are calculated.

[0106] Protein purity = using Imag J software to analyze the SDS-PAGE detection image and obtain the ratio of the grayscale of the corresponding protein band to the grayscale of the total protein bands in the whole lane.

[0107] Total protein amount = protein concentration measured by Bradford method × volume of protein solution.

[0108] The results showed that 1 mL of SSX1 protein solution was purified, with a protein purity of about 95%. The SSX1 protein concentration measured by the Bradford method was 1.8 mg / mL, and the total amount of SSX1 protein purified was 1.8 mg, that is, 1.8 mg of SSX1 protein was purified from 80 mL of culture product, with a high yield.

[0109] Comparative Example 1: 8M urea dissolution of inclusion bodies and purification of SSX1 protein

[0110] The conditions for gene synthesis, expression vector construction, recombinant bacteria construction, protein expression, bacterial cell lysis and inclusion body preparation were the same as those in Examples 1-4.

[0111] Add a dissolution buffer containing 8 M urea to the inclusion bodies and shake at low temperature (2-8°C) for 2 h. The dissolution buffer containing 8 M urea contains 20 mM phosphate, 500 mM sodium chloride, 10 mM imidazole, 8 M urea, 5% glycerol, 1 mM PMSF, 2 mM TCEP, pH 7.5. Centrifuge at 10000g for 10 min to separate the supernatant and precipitate, and filter the supernatant using a 0.22 μm syringe filter.

[0112] The SSX1 protein purification process was the same as in Example 5, except that the SSX1 protein chaotropic agent (0.3% Sarkosyl, 20 mM CHAPS, 50 mM glycine) in the purification buffer was replaced with 8 M urea, and the SSX1 protein containing 8 M urea was purified.

[0113] Depend on Figure 2 It can be seen that the dissolution buffer containing 8 M urea dissolves a large amount of SSX1 protein, and the purified protein contains a small amount of SSX1 protein dimer. The purity and total amount of purified protein were calculated.

[0114] Protein purity = using Imag J software to analyze the SDS-PAGE detection image and obtain the ratio of the grayscale of the corresponding protein band to the grayscale of the total protein bands in the whole lane.

[0115] Total protein amount = protein concentration measured by Bradford method × volume of protein solution.

[0116] The results showed that 15 mL of SSX1 protein solution was purified, with a protein purity of about 95%. The SSX1 protein concentration measured by the Bradford method was 0.16 mg / mL, and the total amount of SSX1 protein purified was 2.4 mg, that is, 2.4 mg of SSX1 protein was purified from 80 mL of culture product.

[0117] Comparative Example 2: SSX1 protein dialysis refolding

[0118] The purified SSX1 protein containing 8 M urea obtained in Comparative Example 1 was added to a pre-treated dialysis bag and dialyzed in the following solutions at 6° C.:

[0119] Dialysis buffer 1: 50 mM Tris, 150 mM NaCl, 6 M Urea, pH 7.4.

[0120] Dialysis buffer 2: 50 mM Tris, 150 mM NaCl, 4 M Urea, 1 mM EDTA, 2 mM GSH, 0.2 mM GSSG, 10% Glycerol, 1% Glycine, 0.02% Tween-80, pH 7.4.

[0121] Dialysis buffer 3: 50 mM Tris, 150 mM NaCl, 2 M Urea, 1 mM EDTA, 2 mM GSH, 0.2 mM GSSG, 10% Glycerol, 1% Glycine, 0.02% Tween-80, pH 7.4.

[0122] Dialysis buffer 4: 50 mM Tris, 150 mM NaCl, 10% Glycerol, 2 mM TCEP, 0.02% Tween-80, pH 7.4.

[0123] Dialysis buffer 5: 10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 150 mM NaCl, 10% Glycerol, 2 mM TCEP, 0.02% Tween-80, pH 7.4.

[0124] During dialysis, 1 mM PMSF was added to the protein solution and stirred slowly with a magnetic stirrer. Each time the dialysis buffer was changed, 30 μL of the protein solution was taken for SDS-PAGE detection.

[0125] Depend on Figure 3 It can be seen that when the SSX1 protein purified from inclusion bodies was dissolved in a dissolution buffer containing 8M urea, precipitation occurred during dialysis refolding, the dimer protein was converted into a monomer protein or precipitated, and the concentration of the target protein was significantly reduced. The dialysis refolding yield, protein purity and total protein amount were calculated.

[0126] Dialysis renaturation yield = total amount of protein obtained by dialysis renaturation / total amount of protein added to the dialysis bag for dialysis.

[0127] Protein purity = using Imag J software to analyze the SDS-PAGE detection image and obtain the ratio of the grayscale of the corresponding protein band to the grayscale of the total protein bands in the whole lane.

[0128] Total protein amount = protein concentration measured by Bradford method × volume of protein solution.

[0129] The results showed that 14.5 mL of SSX1 protein solution was obtained by dialysis renaturation, with a protein purity of about 95%, an SSX1 protein concentration of 0.082 mg / mL, a total amount of SSX1 protein obtained by dialysis renaturation of 1.19 mg, and a dialysis renaturation yield of 49.6%, that is, 80 mL of culture product finally obtained 1.19 mg of SSX1 protein.

[0130] Comparative Example 3: Protein expression without low temperature treatment during autoinduction culture

[0131] The SSX1 protein was expressed as in Example 3, but during the auto-induction expression: 1‰ of the inoculum was inoculated into 80 mL of the auto-induction medium, cultured at 37°C, 220 rpm for 2 h, and then maintained at 37°C, 220 rpm for 16 h.

[0132] The bacterial cells were collected, lysed and inclusion bodies were prepared according to the method of Example 4, and the inclusion bodies were solubilized and SSX1 protein was purified according to the method of Example 5.

[0133] The results showed that the high pH dissolution buffer containing SSX1 protein chaotropic agent was difficult to dissolve SSX1 protein in inclusion bodies, and a large amount of SSX1 protein still existed in the precipitate after dissolution. The concentration of SSX1 protein finally purified was lower than the detection limit of Bradford method. The SSX1 protein expressed by continuous culture at 37℃ formed typical inclusion bodies, and strong denaturants were required to fully dissolve the SSX1 protein.

[0134] Example 6. Detection of SSX1 protein immunoactivity: ELISA

[0135] The SSX1 proteins purified in Example 5, purified in Comparative Example 1, and dialyzed and refolded in Comparative Example 2 were coated on microplates, respectively. The immunoreactivity of the three groups of proteins was determined using a 3-fold gradient dilution of the Anti-SSX1 polyclonal antibody. A four-parameter curve was fitted with the logarithm of the antibody dilution ratio as the abscissa and the signal value as the ordinate ( Figure 4 ).

[0136] The results showed that the signal value measured by the purified SSX1 protein in Comparative Example 1 was significantly lower than the signal values ​​measured by the renatured SSX1 protein in Comparative Example 2 and the purified SSX1 protein in Example 5. The immune activity of the SSX1 protein purified in Example 5 (EC50=0.1054) was higher than the immune activity of the SSX1 protein obtained by dialysis renaturation in Comparative Example 2 (EC50=0.1495), and was much higher than the immune activity of the purified SSX1 protein in Comparative Example 1 (EC50 greater than 0.2951).

[0137] Example 7. Detection kit for SSX1-specific IgG antibodies in human serum: chemiluminescence method

[0138] This kit mainly includes magnetic separation reagent, sample diluent, cleaning solution, enzyme-labeled anti-human IgG antibody reagent, chemiluminescent substrate, calibrator, and quality control product.

[0139] 1. Steps for preparing magnetic separation reagent

[0140] 1) Take an appropriate amount of tosyl magnetic particles and place them in a magnetic field to separate the magnetic particles, remove the supernatant, and add sodium borate solution to resuspend them;

[0141] 2) Add the corresponding amount of SSX1 protein and vortex to mix. Add the corresponding amount of ammonium sulfate solution, vortex to mix, and then incubate on a horizontal shaker at 37°C and 500 rpm for 18 hours;

[0142] 3) Separate the magnetic particles in a magnetic field, remove the supernatant, add blocking solution for blocking, and incubate on a horizontal shaker at 37°C and 500 rpm for 6 hours;

[0143] 4) Magnetic field separation of magnetic particles: remove the supernatant, wash 4 times, add magnetic particle storage solution and resuspend to obtain magnetic separation reagent.

[0144] 2. Detection method of SSX1-specific IgG antibodies in human serum

[0145] 1) Mix 20 μL of magnetic separation reagent and 80 μL of sample diluent, incubate at 37°C with shaking for 30 min, remove the supernatant, wash 5 times to remove other non-specific binding components, and obtain a magnetic particle-antigen-IgG complex;

[0146] 2) Add 100 μL of HRP-labeled anti-human IgG antibody working solution to the magnetic particle-antigen-IgG complex, incubate at 37° C. with shaking for 30 min, remove the supernatant, wash 5 times to remove unbound enzyme-labeled secondary antibody, and obtain a magnetic particle-antigen-IgG-anti-human IgG antibody-HRP complex;

[0147] 3) adding 100 μL of luminescent substrate to the magnetic particle-antigen-IgG-anti-human IgG antibody-HRP complex, and detecting the luminescent intensity within 4 minutes of incubation;

[0148] 4) Using a calibrator of known concentration to draw a luminescence intensity standard curve, and comparing the luminescence intensity obtained in step 3) with the standard curve to calculate the content of specific IgG in the serum sample to be tested.

[0149] Magnetic separation reagents were prepared using the SSX1 proteins purified in Example 5, purified in Comparative Example 1, and dialyzed and renatured in Comparative Example 2, respectively, and the magnetic separation reagents were used to detect SSX1 antibody-positive human serum samples.

[0150] Depend on Figure 5 It can be seen that when the SSX1 protein purified from the inclusion body was dissolved in a dissolution buffer containing 8M urea, and the renatured protein and the unrenatured protein were used for the detection of SSX1 antibody-positive human serum samples, the detection signal value of the SSX1 protein after dialysis renaturation in Comparative Example 2 was significantly higher than the detection signal value of the SSX1 protein purified (without dialysis renaturation) in Comparative Example 1. In Example 5, the SSX1 protein purified from the inclusion body was dissolved in a high pH dissolution buffer containing an SSX1 protein chaotropic agent, and the prepared magnetic separation reagent could achieve a higher signal value for detecting SSX1 antibody-positive human serum samples without the need for cumbersome renaturation steps.

[0151] summary

[0152] In summary, the SSX1 protein preparation method of the present invention is compared with the conventional method and is listed in Table 1.

[0153] Table 1

[0154]

[0155]

[0156] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. A method for recombinantly expressing human SSX1 protein, comprising: (1) providing a recombinant Escherichia coli cell, wherein the Escherichia coli cell comprises a recombinant expression cassette, wherein the recombinant expression cassette comprises a human SSX1 protein coding sequence; (2) culturing the recombinant E. coli cells of (1) to express human SSX1 protein; after expression, lysing the cells to obtain lysate; and isolating inclusion bodies; (3) treating the inclusion bodies of (2) with a human SSX1 protein solubilizing agent at high pH; dissolving the protein with a high pH dissolution buffer containing a human SSX1 protein solubilizing agent; purifying with a purification buffer containing a human SSX1 protein solubilizing agent to obtain an active human SSX1 protein purified product; wherein the human SSX1 protein solubilizing agent comprises: 0.1-1% Sarkosyl, 10-100mM CHAPS, 10-120mM glycine, and the high pH is pH10.0-13.

0.

2. The method according to claim 1, characterized in that In step (1), the culture is carried out using an autoinduction medium, and the autoinduction medium does not contain a chemical inducer such as IPTG; preferably, the autoinduction medium comprises: peptone, yeast extract, glycerol, lactose, glucose, Na2HPO4, NH4Cl, KH2PO4, Na2SO4, MgSO4.

3. The method according to claim 1, characterized in that In step (1), the culture is first carried out at a temperature of 37±3°C, preferably 37±2°C, and more preferably 37±1°C; then, the culture is changed to a temperature of 20±3°C, preferably 20±2°C, and more preferably 20±1°C.

4. The method according to claim 1, characterized in that In step (2), the cells are treated with a lysis buffer sufficient to cause cell lysis, so that the cells are lysed; preferably, the lysis buffer contains an effective amount of: lysozyme, phosphate, sodium chloride, imidazole, glycerol, TCEP, PMSF; preferably, the lysis buffer has a pH of 7.5±0.5 (preferably pH 7.5±0.3, more preferably pH 7.5±0.2 or pH 7.5±0.1); Preferably, after treatment with the lysis buffer, the cells are physically disrupted; more preferably, the cells are ultrasonically disrupted in an ice bath; Preferably, nuclease and MgCl2 are added to the lysate, and the mixture is incubated at 25±3°C (preferably, 25±2°C or 25±1°C); and inclusion bodies are separated and obtained.

5. The method according to claim 1, characterized in that In step (3), the high pH dissolution buffer comprises: a human SSX1 protein chaotropic agent, and: phosphate, sodium chloride, imidazole, glycerol, PMSF, and TCEP.

6. The method according to claim 1, characterized in that In step (3), the purification buffer containing the human SSX1 protein dissolving agent comprises: human SSX1 protein dissolving agent, as well as phosphate, sodium chloride, imidazole, and glycerol; preferably, the purification buffer has a pH of 7.5±0.

5.

7. The method according to claim 1, characterized in that The amino acid sequence of the human SSX1 protein is shown in SEQ ID NO:2; preferably, the coding sequence of the human SSX1 protein is shown in SEQ ID NO:

1.

8. Use of the method according to any one of claims 1 to 7 for recombinantly expressing human SSX1 protein, wherein the human SSX1 protein has high immunological activity.

9. A kit for recombinantly expressing human SSX1 protein, characterized in that: The kit comprises: (a) a high pH dissolution buffer containing a human SSX1 protein dissolving agent; the human SSX1 protein dissolving agent comprises: 0.1-1% Sarkosyl, 10-100 mM CHAPS, 10-120 mM glycine, and the high pH is pH 10.0-13.0; (b) a recombinant E. coli cell, wherein the E. coli cell comprises a recombinant expression cassette, wherein the recombinant expression cassette comprises a human SSX1 protein coding sequence; Optionally also include: (c) autoinduction medium comprises: peptone, yeast extract, glycerol, lactose, glucose, Na2HPO4, NH4Cl, KH2PO4, Na2SO4, MgSO4, and does not contain chemical inducers such as IPTG; (d) a purification buffer containing a human SSX1 protein dissolving agent, comprising: a human SSX1 protein dissolving agent, and phosphate, sodium chloride, imidazole, and glycerol; preferably, the purification buffer has a pH of 7.5±0.5; (e) lysis buffer; preferably, the lysis buffer comprises effective amounts of: lysozyme, phosphate, sodium chloride, imidazole, glycerol, TCEP, PMSF; (f) nuclease and MgCl2; (g) Purification buffer; preferably, it comprises: SSX1 protein chaotropic agent, phosphate, sodium chloride, glycerol, imidazole; preferably, the purification buffer has a pH of 7.5±0.

5.

10. Use of the kit according to claim 9 in recombinant expression of human SSX1 protein.